{"schema_version":"secwatch.filing_event.v1","accession":"0001730463-24-000021","form_type":"8-K","ticker":"AUTL","cik":"0001730463","company_name":"Autolus Therapeutics plc","filed_at":"2024-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.291638+00:00","generated_at":"2026-06-04T19:53:38.367997+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Autolus FY2023 net loss $208.4M; raises $600M via BioNTech deal and offering; CDO resigns","bullets":["Net loss for FY2023 was $208.4M ($1.20 diluted EPS) vs $148.8M in 2022; cash at year-end $239.6M.","In Feb 2024, closed BioNTech collaboration ($250M upfront) and $350M ADS offering for $600M gross proceeds to fund obe-cel launch.","BLA for obe-cel in r/r adult B-ALL submitted to FDA; PDUFA target action date Nov 16, 2024; MAA submitted to EMA.","CDO Dr. Edgar Braendle resigns effective March 2024; will consult. Chris Williams promoted to CBO, Alex Driggs to SVP Legal.","Obe-cel Phase 1 SLE trial open for enrollment; initial data expected late 2024; Nucleus manufacturing facility obtained MIA for commercial supply."],"urls":{"canonical":"https://secwatch.observer/filing/0001730463-24-000021","json":"https://secwatch.observer/filing/0001730463-24-000021.json","markdown":"https://secwatch.observer/filing/0001730463-24-000021.md","text":"https://secwatch.observer/filing/0001730463-24-000021.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730463/000173046324000021/0001730463-24-000021-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730463/000173046324000021/autl-20240314.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T19:53:38.367997+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5c8bfc1ef7f8f563d20270f162c54705052c2d90","claim":"Autolus Therapeutics plc reported financial results for the full year ended December 31, 2023.","evidence_excerpt":"On March 14, 2024, Autolus Therapeutics plc (the “ Company ”) issued a press release announcing its recent business highlights and financial results for year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1730463/000173046324000021/0001730463-24-000021-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}